What is the evidence base for Selank (Intranasal)?

Selank (Intranasal)'s evidence base sits at research level investigational. The references on this page summarise 1 primary publication supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The sourcing / quality / procurement interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

What should I look for in Selank (Intranasal) sourcing and quality?

Acceptable Selank (Intranasal) certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 751 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

Is Selank (Intranasal) safe during pregnancy or breastfeeding?

Selank (Intranasal), like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

What is the mechanism of action of Selank (Intranasal)?

Same Selank molecule; olfactory pathway bypasses BBB. For sourcing and quality-control applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Same Selank molecule; olfactory pathway bypasses BBB. The sourcing / quality / procurement interpretation focuses on the pathway-level detail rather than on any single high-level summary.

What class of compound is Selank (Intranasal)?

Selank (Intranasal) is classified as a Tuftsin-derived heptapeptide (intranasal). Within this class, alternative names and analogues include Intranasal Selank. The class-level pharmacology shapes both the clinical applications and the safety profile; the sourcing / quality / procurement literature treats Selank (Intranasal) alongside its class peers when evaluating relative merits.

Home/ Compounds/ Selank (Intranasal)

Selank (Intranasal)

Sourcing Guide

Procurement-quality evaluation of Selank (Intranasal) centres on six markers: lot-specific COA availability, HPLC purity ≥98%, mass spec confirmation matching 751 Da, endotoxin testing for injectable routes, vendor regulatory disclosure, and cold-chain shipping options. Same Selank molecule; olfactory pathway bypasses BBB. The QC discipline applies regardless of the application; sourcing standards do not relax for any particular use case.

Sourcing / Quality / Procurement Applications

Mass Spectrometry VerificationVendor ComparisonCOA ReviewStorage ProtocolLyophilisation Quality

Key Takeaways

Procurement lens: Selank (Intranasal) sourcing requires lot-specific COA, HPLC purity ≥98%, mass spec confirmation matching 751 Da.
Mechanism: Same Selank molecule; olfactory pathway bypasses BBB.
Storage: lyophilised at -20°C for 18-24 months; reconstituted at 4°C for 14-28 days.
Vendor tier: pharmaceutical-grade compounded > reputable research-grade > grey-market (3-5x cost differential; quality differential substantially larger).
Sourcing-validated stack partners: BPC-157, TB-500, GHK-Cu.

Sourcing / Quality / Procurement Mechanism

Same Selank molecule; olfactory pathway bypasses BBB. Sourcing implications: the mechanism dictates which analytical assays are appropriate for QC, which storage conditions preserve activity, and which reconstitution and use practices matter. The subsections below cover HPLC and analytical identity, COA evaluation and red flags, reconstitution and storage, and vendor tier comparison for Selank (Intranasal).

Vendor tier comparison and price discipline

Three vendor tiers operate in the Selank (Intranasal) market: pharmaceutical-grade compounded prescription (physician-supervised, full COA, ICP-MS where relevant, highest cost), reputable research-chemical vendors (full COA, lot-specific, mid-tier cost), and grey-market unverified sources (template or absent COA, unverifiable supply chain, lowest cost). The price differential between tiers is roughly 3–5x; the quality differential is substantially larger and concentrated in the bottom tier.

HPLC purity and analytical identity

Minimum acceptable HPLC purity for Selank (Intranasal) is ≥98% in research-grade material. Mass spec confirmation should show the characteristic m/z of 751 (M+H)+. Contaminant peaks above 1% in the HPLC trace warrant quantification on the COA and — ideally — structural identification of the major impurities.

COA evaluation and red flags

Acceptable Selank (Intranasal) certificates of analysis specify: (1) lot number matching the vial, (2) HPLC purity with chromatographic trace, (3) mass spec confirmation, (4) endotoxin testing for SubQ-route use, and (5) issuance from an accredited third-party laboratory. Template COAs that cannot be traced to a specific lot, COAs missing endotoxin data for injectable material, and COAs issued by the vendor's own laboratory rather than a third party are all sourcing red flags.

Sourcing / Quality / Procurement Applications

Vendor Comparison

Sourcing Selank (Intranasal) for vendor comparison use requires the same QC discipline as any peptide procurement: lot-specific COA, HPLC purity ≥98%, mass spec confirmation, endotoxin testing for injectable routes. Application-specific use does not relax the sourcing standard.

Lot Variability

For users targeting lot variability, the sourcing question is whether the chosen vendor consistently delivers analytical-spec material across lots. Repeated re-orders from the same vendor with mid-cycle COA spot-checks is the procurement pattern that catches lot drift before it affects results.

Vial Inspection

Pharmaceutical-grade compounded Selank (Intranasal) is the lowest-risk sourcing path for vial inspection use where the route permits, particularly for users with clinical supervision. Research-grade material from accredited vendors is the practical alternative; grey-market sourcing is not appropriate for this application.

Storage Protocol

Sourcing Selank (Intranasal) for storage protocol use requires the same QC discipline as any peptide procurement: lot-specific COA, HPLC purity ≥98%, mass spec confirmation, endotoxin testing for injectable routes. Application-specific use does not relax the sourcing standard.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	Intranasal	300 mcg per spray	8–12 weeks on / 4 weeks off
Conservative starter	Intranasal	180 mcg per spray	4–6 weeks initial cycle
Sourcing Guide focus	Intranasal	300 mcg per spray	2-3 sprays daily for 2-4 week courses
Maintenance phase	Intranasal	210 mcg per spray	Ongoing with periodic pauses

Dose timing for Selank (Intranasal) is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Selank (Intranasal) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from experienced peptide buyers.

Selank (Intranasal) + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Selank (Intranasal)'s mechanism in sourcing / quality / procurement protocols.
Selank (Intranasal) + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Selank (Intranasal)'s mechanism in sourcing / quality / procurement protocols.
Selank (Intranasal) + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with Selank (Intranasal)'s mechanism in sourcing / quality / procurement protocols.
Selank (Intranasal) + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Selank (Intranasal)'s mechanism in sourcing / quality / procurement protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved (Russia approved)

Excellent. Mild nasal irritation possible.

Lens-specific safety considerations for sourcing / quality / procurement use of Selank (Intranasal): Excellent. Mild nasal irritation possible. Additional sourcing / quality / procurement monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Selank in GAD

PMID 21443549

Selank (Intranasal) vs Related Peptides

Compound	Profile	Onset	Best For
Selank (Intranasal)	Tuftsin-derived heptapeptide (intranasal)	CNS effect hours	Sourcing Guide
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

Reconstitution best practices?

Use sterile bacteriostatic water (0.9% benzyl alcohol). Inject the BAC water down the side of the vial, not directly onto the lyophilised powder. Allow gentle dissolution; do not shake vigorously — swirl the vial. Label the reconstituted vial with concentration and date.

Pharmaceutical-grade versus research-grade?

Pharmaceutical-grade is GMP-manufactured, COA-backed, prescription-dispensed material with comprehensive quality assurance. Research-grade is laboratory-purpose, COA-backed, not dispensed under prescription. Quality varies substantially between research-grade vendors; pharmaceutical-grade has a tighter quality distribution and a higher price.

What should I check on a Selank (Intranasal) COA?

Acceptable certificates: lot-specific (not template), HPLC purity ≥98%, mass spec confirmation matching 751 Da, endotoxin testing for injectable routes, accredited third-party lab issuance. Template COAs and missing endotoxin data are red flags.

Vendor red flags?

Six markers: (1) no lot-specific COAs available, (2) HPLC purity only, no copper or stoichiometry assay where applicable, (3) no physical address or regulatory disclosure, (4) no cold-chain shipping option, (5) no refund policy for failed-QC lots, (6) therapeutic claims about research material. Multiple flags = walk away.

What is Selank (Intranasal)?

Selank (Intranasal) (also known as Intranasal Selank) is a 7-residue tuftsin-derived heptapeptide (intranasal) with a molecular weight of 751 Da and a plasma half-life of CNS effect hours. Same Selank molecule; olfactory pathway bypasses BBB. The compound is studied primarily in the sourcing / quality / procurement domain for the applications outlined above.

What is the standard dosing protocol for Selank (Intranasal)?

Conventional Selank (Intranasal) dosing is 300 mcg per spray 2-3 sprays daily for 2-4 week courses via intranasal. For sourcing and quality-control use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

Clinical Protocol

Start a Selank (Intranasal) Protocol

Alukard provides GMP-certified physician-supervised sourcing with GMP-certified Selank (Intranasal) and Pharmaceutical-grade compounds with full COA documentation.

Get Protocol

Quick Facts

Molecular weight: 751 Da
Sequence length: 7 aa
Half-life: CNS effect hours
WADA: Not on prohibited list
FDA: Unapproved (Russia approved)

Stack Partners

BPC-157

TB-500

GHK-Cu

Ipamorelin

Semax

Research Note

All sourcing / quality / procurement applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Selank (Intranasal) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

GMP-certified physician-supervised sourcing

Start Your Sourcing / Quality / Procurement Protocol for Selank (Intranasal)

Alukard provides GMP-certified physician-supervised sourcing with Pharmaceutical-grade compounds with full COA documentation.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised